Related Experiment Video
Updated: Jul 2, 2026
09:15
Orthotopic Rat Kidney Transplantation: A Novel and Simplified Surgical Approach
Published on: May 7, 2019
Complement 5a receptor inhibition improves renal allograft survival
Faikah Gueler1, Song Rong, Wilfried Gwinner
1Department of Nephrology, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. fgueler@googlemail.com
Journal of the American Society of Nephrology : JASN
|August 30, 2008
Summary
Targeting the complement 5a receptor (C5aR) significantly improves kidney transplant survival by reducing apoptosis and inflammation. Blocking C5aR offers a promising therapeutic strategy for preventing acute renal allograft rejection.
Area of Science:
- Immunology
- Transplantation Medicine
- Nephrology
Background:
- Complement activation is crucial in transplant rejection, apoptosis, and inflammation.
- The complement 5a receptor (C5aR) role in renal allograft rejection requires further elucidation.
Purpose of the Study:
- To investigate the role of C5aR in human and murine renal allograft rejection.
- To evaluate the therapeutic potential of C5aR antagonism in preventing kidney transplant rejection.
Main Methods:
- Assessed C5aR expression in human renal allografts and an experimental mouse model.
- Administered a C5aR antagonist to recipient mice pre-transplantation.
- Conducted in vitro studies on endothelial cells and peripheral blood mononuclear cells.
Main Results:
- Increased C5aR expression observed in rejecting human and murine renal allografts.
- C5aR antagonist treatment improved long-term allograft survival from 0% to 75% and reduced apoptosis.
- Antagonist treatment attenuated monocyte/macrophage infiltration and inhibited T cell priming.
Conclusions:
- C5aR plays a significant role in mediating acute kidney allograft rejection.
- Pharmaceutical targeting of C5aR presents a potential therapeutic avenue for transplantation medicine.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...